- July 22, 2016Frost & Sullivan honored recipients of its 2016 Excellence in Best Practices Awards at a gala held Wednesday, July 13, in Asheville, NC at the Omni Grove Park Inn. With a festive ambiance and exciting Awards, the event brought together top executives to celebrate their success. The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future.
CapsoVision, Inc. Honored by Frost & Sullivan for Ongoing Technology Advancement and Market Growth in the Capsule Endoscopy MarketMay 19, 2016CapsoVision, Inc., a Silicon Valley medical device innovator, announces that they have been recognized by Frost & Sullivan as the recipient of the 2016 European Enabling Technology Leadership award. CapsoVision had previously been awarded by Frost & Sullivan for excellence in product differentiation in 2013.
- March 4, 2016CapsoVision is pleased to announce it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for CapsoCam® SV-1. The clinical study submitted to the FDA was designed to demonstrate that CapsoCam SV-1 is safe and effective for the intended use of visualization of the small bowel mucosa in adults, and it may be used as a tool in the detection of abnormalities of the small bowel The study compared CapsoCam SV-1 to PillCam® SB2. Results from the multi-center study demonstrate that CapsoCam SV-1 performs in a manner that is substantially equivalent to PillCam SB2 and has a comparable safety profile as PillCam SB2. In a patient questionnaire administered during the study, ~80% patients indicated that they preferred the CapsoCam system to the PillCam system.